During the past decade, Saitama Cancer Center; Thoracic Oncology conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 6 clinical trials were completed, i.e. on average, 120% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 5 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saitama Cancer Center; Thoracic Oncology" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Chugai Pharmaceutical" with 1 trials sponsored, "Elevar Therapeutics" with 1 trials sponsored, "NCIC Clinical Trials Group" with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saitama Cancer Center; Thoracic Oncology" #1 collaborator was "Japan Lung Cancer Society" with 1 trials as a collaborator and "Sumitomo Pharma Oncology, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Saitama Cancer Center; Thoracic Oncology" are "Breast Cancer" (1 trials), "Colorectal Carcinoma" (1 trials), "Extensive Disease Small Cell Lung Cancer" (1 trials), "Gastric Adenocarcinoma" (1 trials) and "Gastric Cancer" (1 trials). Many other conditions were trialed in "Saitama Cancer Center; Thoracic Oncology" in a lesser frequency.

Most popular intervention types in "Saitama Cancer Center; Thoracic Oncology" are "Drug" (6 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (3 trials), "Placebo" (3 trials), "Paclitaxel" (2 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "Saitama Cancer Center; Thoracic Oncology" are 6 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Saitama Cancer Center; Thoracic Oncology". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Saitama Cancer Center; Thoracic Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Saitama Cancer Center; Thoracic Oncology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".